

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently Amended) A method for treating an inflammatory disease, an inflammatory disorder or a cancer selected from the group consisting of colorectal cancer, prostate cancer, pancreatic cancer, and lung cancer in a patient, comprising:

simultaneous or step-wise administering of curcumin, curcumin analogue or derivative thereof and at least one NSAID to the patient, the curcumin, curcumin analogue or derivative thereof being administered in an amount sufficient to reduce the NSAID concentration needed while maintaining the same therapeutic effect as compared to administering the NSAID alone,

wherein the NSAID is selected from the group consisting of ketorolac, nabumetone, salsalate, diclofenac, indomethacin, nabumetone, phenylbutazone, oxyphenbutazone, dipyrone, ramifenazone, tenoxicam, valdecoxib, parecoxib, etoricoxib, celecoxib, sulindac, sulindac sulfide, exisulind, ibuprofen, naproxen, naproxen sodium, rofecoxib, nimesulide, aspirin, tolmetin, fenoprofen, flurbiprofen, loxoprofen, vedaprofen, meclofenamic acid, meclofenamate sodium, tolfenamic acid, acetaminophen, flunixin, piroxicam, oxaprozin, meloxicam, ketoprofen, etodolac and diflunisal, or a salt or prodrug thereof.

2. (Cancelled)
3. (Previously Presented) The method according to claim 1, wherein the drug is selected from the group consisting of celecoxib, nimesulide, sulindac and sulindac sulfide, or salts or prodrugs thereof.
4. (Previously Presented) The method according to claim 1, wherein said drug is not celecoxib or derivatives, analogues, salts or prodrugs thereof.
5. (Currently Amended) The method according to claim 1, wherein said curcumin, curcumin analogue or derivative thereof is a curcumin analogue or derivative selected from the group consisting of demethoxycurcumin and bisdemethoxycurcumin.
- 6-8. (Cancelled)
9. (Currently Amended) The method according to claim 1 [[6]], wherein said curcumin and said NSAID are administered not within the same formulation.
10. (Currently Amended) The method according to claim 1 [[6]] wherein said NSAID is celecoxib, nimesulide, sulindac or sulindac sulfide or derivatives, analogues, salts or prodrugs thereof.

11. (Currently Amended) The method according to claim 1 [[6]], wherein said NSAID is a drug other than celecoxib, or a drug other than sulindac, or a drug other than sulindac sulfide or derivatives, analogues, salts or prodrugs thereof.

12. (Currently Amended) A method for inhibiting cancer cell growth, comprising:
contacting cancer cells with an effective amount of ~~a formulation comprising~~
curcumin, a curcumin analogue or derivative thereof and an effective amount of at least
one NSAID selected from the group consisting of ketorolac, nabumetone, salsalate,
diclofenac, indomethacin, nabumetone, phenylbutazone, oxyphenbutazone, dipyron,
ramifenazone, tenoxicam, valdecoxib, parecoxib, etoricoxib, celecoxib, sulindac, sulindac
sulfide, exisulind, ibuprofen, naproxen, naproxen sodium, rofecoxib, nimesulide, aspirin,
tolmetin, fenoprofen, flurbiprofen, loxoprofen, vedaprofen, meclofenamic acid,
meclofenamate sodium, tolfenamic acid, acetaminophen, flunixin, piroxicam, oxaprozin,
meloxicam, ketoprofen, etodolac and diflunisal, or a salt or prodrug thereof,

wherein the curcumin, curcumin analogue or derivative thereof is present in an
amount sufficient to reduce the NSAID concentration needed while maintaining the same
therapeutic effect as compared to administering the at least one NSAID alone, and

wherein the curcumin, curcumin analogue or derivative thereof and the at least one
NSAID are administered simultaneously, sequentially or separately.

13. (Currently Amended) The method according to claim 12, wherein said cells are contacted with a single formulation comprising both the curcumin, curcumin analogue or derivative thereof and at least one NSAID.

14. (Currently Amended) The method according to claim 12, wherein said cells are contacted with a formulation comprising the curcumin, curcumin analogue or derivative thereof, followed by contacting with a second formulation containing said at least one NSAID.

15. (Currently Amended) The method according to claim 12 wherein said cells are contacted with a formulation containing said at least one NSAID, followed by contacting with a second formulation ~~containing~~ comprising the curcumin, curcumin analogue or derivative thereof.

16-20. (Cancelled)

21. (Currently Amended) The method according to claim 1 ~~[[20]]~~, wherein said cancer is colorectal or colon cancer.

22. (Cancelled)

23. (Currently Amended) The method according to claim 1, wherein said inflammatory disease or inflammatory disorder is selected from the group consisting of arthritis, rheumatoid arthritis (RA), spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, acne vulgaris, acute respiratory distress syndrome, Addison's disease, allergic rhinitis, allergic intraocular inflammatory diseases, ANCA-associated small-vessel vasculitis, atherosclerosis, atopic dermatitis, autoimmune hemolytic anemia, autoimmune hepatitis, Behcet's disease, Bell's palsy, cerebral ischemia, Cogan's syndrome, dermatomyositis and psoriatic arthritis.

24. (Previously Presented) The method according to claim 23, wherein said inflammatory disease or disorder is arthritis.

25. (Previously Presented) The method according to claim 1, further comprising administering one or more additional active ingredients, selected from antibiotics, conventional anti-cancer and anti-inflammatory agents.

26-31. (Cancelled)

32. (Currently Amended) A combination of two pharmaceutical compositions, comprising:

a first composition comprising an effective amount of at least one NSAID drug selected from the group consisting of ketorolac, nabumetone, salsalate, diclofenac, indomethacin, nabumetone, phenylbutazone, oxyphenbutazone, dipyrrone, ramifenazone, tenoxicam, valdecoxib, parecoxib, etoricoxib, celecoxib, sulindac, sulindac sulfide, exisulind, ibuprofen, naproxen, naproxen sodium, rofecoxib, nimesulide, aspirin, tolmetin, fenoprofen, flurbiprofen, loxoprofen, vedaprofen, meclofenamic acid, meclofenamate sodium, tolfenamic acid, acetaminophen, flunixin, piroxicam, oxaprozin, meloxicam, ketoprofen, etodolac and diflunisal, or a salt or prodrug thereof; and

a second composition comprising an effective amount of curcumin, a curcumin analogue or derivative thereof,

the combination ~~[[is]]~~ being intended for administering to a subject for treatment of an inflammatory disorder or a cancer selected from the group consisting of colorectal cancer, prostate cancer, pancreatic cancer, and lung cancer ~~cancer or inflammation~~,

wherein the ~~said~~ second composition is administered after administering the ~~said~~ first composition.

33-45. (Cancelled)